The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically or orally acceptable carrier for administration.
-
Paragraph 00142-00143; 00210-00211
(2021/05/15)
β-adrenergic agonists
The instant invention concerns certain α-heterocyclic ethanol amines wherein the amine group is substituted with various alkyl and unsaturated alkyl groups optionally further substituted with hydroxy, or alkoxy groups of the formula: STR1 These compounds are useful as growth promotion agents in animals.
-
(2008/06/13)
More Articles about upstream products of 123788-44-3